27633 Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: Pooled Results from two phase 3 studies

Abstract

Atopic dermatitis (AD) is a highly pruritic inflammatory skin disease that most often begins in childhood and can persist into adolescence and adulthood. Ruxolitinib cream is a Janus kinase (JAK) 1/JAK2 inhibitor in development for the treatment of AD. Two phase 3 randomized studies (TRuE-AD1 [NCT03745638]; TRuE-AD2 [NCT03745651]) enrolled patients aged ≥12 years with AD for ≥2 years with an Investigator’s Global Assessment (IGA) score of 2 or 3 and 3%–20% affected body surface area. A total of 1249 patients were randomized (2:2:1) to twice daily 0.75% ruxolitinib, 1.5% ruxolitinib, or vehicle cream for 8 weeks of double-blind treatment.